Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers — COG0107  

Alzheimer Disease Clinical Trial

Official title: A Phase 1 Study to Assess the Pharmacokinetics of Different Multiple Dose Regimens of CT1812 in Older Healthy Volunteers

Status Completed

Clinical Trial Summary

This an open label study to assess the pharmacokinetics of CT1812 in normal healthy volunteers.

Clinical Trial Description

Open label study to assess PK in 36 older healthy volunteers. Subjects will be screened 35 days prior dose to determine eligibility. On day -1 subjects will be admitted to the clinical research unit and on day 1 will be randomized to receive one of the following doses: 150 mg BID, 150 mg QD or 300 mg QD in the fed state. Subjects will be confined in the Clinical Research Unit where they will continue to receive study drug and complete safety assessments, PK and CSF draws, until day 16 when they will be discharged. ;

Related Conditions & MeSH terms

• Alzheimer Disease

• NCT number: NCT05248672
• Study type: Interventional
• Source: Cognition Therapeutics
• Status: Completed
• Phase: Phase 1
• Start date: February 15, 2022
• Completion date: June 1, 2022